查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2094974

先進治療藥物（ATMP）CDMO市場－2026-2032年全球市場預測

Advanced Therapy Medicinal Products CDMO Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，先進治療藥物 (ATMP) 的 CDMO 市場將成長至 284.6 億美元，複合年成長率為 17.92%。

主要市場統計數據
基準年 2025 89.7億美元
預計年份：2026年 104.3億美元
預測年份 2032 284.6億美元
複合年成長率 (%) 17.92%

先進治療藥物（ATMP）CDMO執行摘要

先進治療藥物（ATMP）的合約研發生產機構（CDMO）服務在將包括細胞療法、基因療法、組織工程產品及其組合在內的先進療法從臨床開發過渡到受監管的商業供應方面發揮核心作用。這種需求源自於自體和異體移植平台的科學複雜性、病毒和非病毒載體的生產、質體DNA供應、無菌包裝和精加工、療效測試、等效性和鑑別控制，以及對患者長期追蹤的要求。與傳統生技藥品的生產不同，ATMP的生產通常需要高度專業化的無塵室基礎設施、封閉式製程系統、低溫物流、經驗證的分析方法以及符合多個司法管轄區良好生產規範（GMP）要求的品管系統。美國食品藥物管理局管理局（FDA）、歐洲藥品管理局（EMA）和日本藥品和醫療設備管理局（PMDA）等監管機構正在製定針對先進療法的專門核准途徑和指南，這進一步增加了對擁有深厚技術、法規和品質專業知識的CDMO合作夥伴的需求。該領域的戰略重要性體現在：核准的細胞和基因療法數量不斷增加，腫瘤學、罕見疾病、免疫學和再生醫學領域的臨床試驗活動不斷擴大，以及在不損害安全性和產品特性的前提下，提高可擴展性、可重複性和成本效益的需求。

ATMP/CDMO產業的變革性變化

隨著研發人員從客製化、人工操作的研究級製程轉向工業化、數位化控制且符合監管要求的生產模式，ATMP CDMO（先進治療產品合約研發生產機構）產業格局正經歷著變革性的轉變。其中一個關鍵轉折點是採用封閉式自動化生產平台，這些平台能夠降低污染風險、提高製程一致性，並在臨床適用的情況下支援分散式或即時生產模式。病毒載體的生產仍然是一個重要的瓶頸，因為慢病毒、腺結合病毒和逆轉錄病毒載體需要複雜的上游和下游工作流程、嚴格的表徵以及可擴展的轉染和細胞生產技術。同時，包括脂質奈米顆粒和基於轉座子的方法在內的非病毒遞送系統正日益受到關注，因為研發人員正在尋求能夠提高可擴展性並減少製程限制的替代方案。品管也正從最終產品測試轉向能夠實現整合製程分析、快速微生物分析、數位化批次記錄和即時出貨批准的策略。監管機構對製程變更後的等效性、分析驗證、療效測試的有效性、原料可追溯性以及供體細胞變異性等方面的要求日益提高。這些變化促使治療藥物研發企業在研發早期階段就選擇合約研發生產機構（CDMO）合作夥伴，尤其是那些能夠提供製程開發、GMP生產、監管文件編制、分析生命週期管理以及全球臨床供應協調等服務的合作夥伴。

人工智慧對ATMP CDMO營運的累積影響

人工智慧 (AI) 正透過加深對製程流程的理解、加速分析結果的解讀以及強化品質決策，開始影響 ATMP CDMO 的運作。在細胞治療生產中，AI 和機器學習可以輔助識別供體差異、培養條件、細胞增殖譜、代謝物趨勢以及包裝外檢測結果等模式。在基因治療和載體生產中，AI 驅動的模型有助於最佳化上游工程參數、提高下游產量、預測雜質並調查批次偏差。 AI 在數位化品管中也發揮著日益重要的作用，例如自動文件審核、環境監測中的異常檢測、關鍵設備的預測性維護以及批次記錄的快速評估。在 ATMP 領域，每個批次都具有臨床意義，產品可比性也十分複雜，AI 透過整合生產、分析、臨床和供應鏈數據來建立更一致的管理策略，從而創造價值。然而，AI 的應用必須確保系統經過驗證、資料完整性管理、可解釋性、網路安全措施以及符合法規要求。因此，AI 的累積影響遠不止於加速生產。它代表著建立一個更強大、更透明、更具適應性的製造生態系統的潛力，該生態系統能夠提高可重複性，降低失敗風險，並支持基於證據的監管申報。

ATMP/CDMO生態系統的關鍵區域洞察

亞太地區在ATMP CDMO（先進治療藥物合約研發生產）領域的地位日益鞏固，這得益於監管現代化、生物醫藥基礎設施的擴展以及中國、日本、韓國、印度、新加坡和澳洲等國臨床研發的蓬勃發展。日本的再生醫學體系、韓國先進的生物製藥生產能力、中國的大規模臨床研究基地以及新加坡的生物醫藥製造生態系統共同推動了該地區的發展動能。北美地區仍然是一個高度成熟的ATMP CDMO區域，擁有大量的臨床試驗、已通過核准的先進療法、大學附屬醫療中心、符合GMP標準的基礎設施以及FDA針對人類基因治療、細胞治療和再生醫學產品的監管指導。拉丁美洲的發展速度相對較慢，巴西和墨西哥是重要的臨床研究和生物製造中心，但該地區面臨的挑戰包括基礎設施不平衡、報銷限制以及監管能力協調的必要性。歐洲受益於歐洲藥品管理局 (EMA) 對先進治療藥物 (ATMP) 的集中監管流程、成熟的藥品生產品質管理規範 (GMP) 專業知識、強大的醫院和學術網路以及跨境臨床研究。德國、法國、義大利、西班牙和英國在先進療法的研發和生產能力方面發揮著重要作用。在中東，隨著醫療保健多元化策略、對臨床基礎設施的投資、基因組學計畫和醫療創新計畫的推進，人們對先進療法的興趣日益濃厚，尤其是在海灣國家尋求先進生物技術能力方面。非洲仍處於起步階段，但在建立臨床研究能力、生物製造夥伴關係、人力資源開發、加強管理體制以及擴大先進生技藥品基礎設施的覆蓋範圍等領域，機會顯而易見。

塑造 ATMP CDMO 策略的關鍵集團洞察

東協正崛起為先進治療藥物（ATMP）服務的重要成長走廊，這得益於新加坡成熟的生物醫藥製造地、泰國的醫學研究舉措、馬來西亞的生物製藥發展以及該地區對細胞療法的廣泛需求。然而，東協各國的能力差異顯著。海灣合作理事會（GCC）的重要性日益凸顯，其成員國正加大對醫療轉型、基因組學、專科藥物和生物技術基礎設施的投資，為先進療法的臨床應用和本地製造夥伴關係創造了長期潛力。歐盟透過其集中核准體系、GMP要求、強制性藥物安全監測和科學諮詢機制，為ATMP提供了最完善的法規環境之一，使其成為跨國公司發展策略中的關鍵區域。金磚國家（BRICS）提供了多元化的機會。中國和印度擁有龐大的患者群體和不斷成長的生物製造能力；巴西和南非在區域臨床和公共衛生領域具有重要意義；俄羅斯儘管面臨地緣政治和監管方面的複雜性，仍然保持著強大的科學研究實力。七國集團（G7）憑藉其先進的監管機構、領先的研究機構、臨床試驗網路、醫保報銷決策者以及塑造全球先進治療產品（ATMP）標準的生產技術，持續發揮著舉足輕重的作用。北約成員國與北美和歐洲的主要先進療法中心高度重合，在這些中心，供應鏈韌性、關鍵醫療基礎設施、生物安全和戰略性生產自主性對於高價值生技藥品和先進療法而言，正日益成為重要的考量。

主要國家對ATMP CDMO發展的見解

美國擁有最成熟的ATMP CDMO服務國家級環境，這得益於其FDA監管路徑、強大的臨床試驗基礎設施、廣泛的轉化研究活動以及涵蓋符合GMP標準的細胞和基因治療生產能力的龐大網路。加拿大憑藉其強大的大學醫院、再生醫學網路和臨床研究基礎設施做出貢獻，而墨西哥由於毗鄰美國，在支持醫療保健製造和臨床開發方面的重要性日益凸顯。巴西憑藉其研究機構和生技藥品英國方面的專業知識以及與注重創新的監管機構的合作，繼續保持其作為主要ATMP中心的地位。德國在GMP生產、工程實力和先進的生物製程能力方面擁有深厚的專業知識，而法國則將醫院研究、公共生物醫學投資和細胞治療開發基礎設施相結合。俄羅斯在生物技術領域擁有豐富的科學和臨床經驗，但國際合作和供應鏈整合受到地緣政治和監管限制。義大利和西班牙憑藉著在大學醫院、臨床試驗活動和細胞治療計畫的經驗，為歐洲做出了重要貢獻。中國正透過積極的臨床研究、對國內生物製造的投資以及不斷完善的細胞和基因治療法規，迅速擴展先進治療產品（ATMP）生態系統。印度憑藉其在疫苗和生技藥品生產、臨床研究能力以及新興的細胞和基因治療舉措的良好記錄，正在建立自身能力。日本因其再生醫學法律規範以及對某些再生醫學產品的早期有條件批准機製而脫穎而出。澳洲透過其健全的臨床試驗體系、醫院網路和生物醫學研究支持ATMP的開發，而韓國則以其先進的生物製造、細胞治療創新以及政府對增強生物製藥競爭力的支持而聞名。

為ATMP/CDMO產業的領導者提供實用建議。

產業領導者應從研發早期階段就優先考慮整合式ATMP CDMO策略，將製程開發、分析驗證、GMP生產、法規遵循計畫和臨床供應物流緊密結合。研發者應選擇在其特定療法領域擁有成熟經驗的合作夥伴，無論是自體細胞療法、異體細胞療法、病毒載體基因療法、基因編輯細胞療法、組織工程產品或聯合ATMP。投資於密封加工、自動化、數位化批記錄、電子身分和監管鏈系統以及低溫物流可以降低營運風險並提高擴充性。品質策略應著重於療效檢測方法的開發、原料合格、可比較方案、污染控制和資料完整性。企業也應實現質體、病毒載體、細胞培養基、一次性系統和特殊試劑等關鍵投入的多元化，以增強供應的連續性。與監管機構的合作應積極主動，包括就生產變更、出庫檢查、長期追蹤和上市後計劃提供早期科學建議和協調。最後，鑑於熟練人員短缺仍然是 ATMP CDMO 行業最持久的障礙之一，經營團隊需要提高員工在 GMP 無菌技術、細胞處理、載體分析、品質保證、法規事務和數位製造方面的能力。

ATMP CDMO 洞察調查方法

本執行摘要採用檢驗的二手研究途徑，基於公開的監管、科學、臨床和行業資訊來源編寫而成。輸入資訊包括主要監管機構的指導意見和公開資訊、關於細胞和基因治療生產的同行評審文獻、臨床試驗註冊數據、公共衛生機構資料、學術出版物、生產標準以及基於GMP的先進治療藥物生產中已記錄的行業實踐。分析採用定性檢驗法，檢視監管趨勢、臨床研發管線活動、生產技術趨勢、供應鏈考量、區域政策舉措。調查方法有意排除市場規模計算、市佔率估計、收入預測或推測性預測。相反，它側重於循證指標，例如法律規範、已批准的治療類別、生產要求、基礎設施建設、臨床研究活動、品質系統需求和技術應用模式。區域、群體和國家的具體見解被整合到說明評估中，以支持對ATMP CDMO趨勢的策略性理解，同時確保符合資料完整性、可追溯性和非推廣性內容標準。

結論：ATMP CDMO發展策略展望

隨著細胞療法、基因療法和再生醫學產品在臨床和商業應用中的拓展，先進治療藥物（ATMP）CDMO產業正成為下一代醫療保健的關鍵驅動力。最具競爭力的CDMO策略將圍繞著特定療法的專業知識、經驗檢驗的GMP基礎設施、強大的分析科學、法規遵循、數位化品質系統和穩健的供應鏈建構。臨床試驗生態系統、監管清晰度、製造投資和人才匯聚的地區發展勢頭最為強勁，但新興地區也在透過生物技術能力建設和醫療創新項目創造新的機會。人工智慧、自動化、封閉式系統和先進分析技術有望提升生產控制和品質績效，但它們的實施必須符合驗證、合規性和病人安全要求。對於研發人員、醫療系統和製造合作夥伴而言，首要任務顯而易見：建構擴充性、合規且科學嚴謹的ATMP CDMO能力，以確保將複雜的治療創新成果惠及病患。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 先進治療藥物（ATMP）CDMO市場：依產品類型分類

  • 細胞治療產品
    • 非幹細胞療法
    • 幹細胞療法
  • 基因治療產品
    • 細胞株療法
    • 體細胞基因治療
  • 組織工程產品

第8章 先進治療藥物（ATMP）CDMO市場：依服務類型分類

  • 分析測試和品管
  • 製造服務
  • 流程開發服務
  • 監管和合規支持

第9章 先進治療藥物（ATMP）CDMO市場：依治療領域分類

  • 循環系統
  • 皮膚科
  • 血液學
  • 神經病學
  • 腫瘤學

第10章 先進治療藥物（ATMP）CDMO市場：依最終用戶分類

  • 學術研究機構
  • 生技公司
  • 製藥公司

第11章 先進治療藥物（ATMP）CDMO市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 先進治療藥物（ATMP）CDMO市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 先進治療藥物（ATMP）CDMO市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • AGC Biologics Inc.
  • Agilent Technologies, Inc.
  • Ajinomoto Bio-Pharma Services
  • Almac Group Ltd.
  • Biomay AG
  • BioSpring GmbH
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • CordenPharma International GmbH
  • Creative Biogene
  • Danaher Corporation
  • Eurofins Scientific SE
  • Evonik Industries AG
  • GenScript Biotech Corporation
  • Lonza Group Ltd.
  • Polypeptide Group AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics Co., Ltd.
  • Sartorius AG
  • Siegfried AG
  • Syneos Health, Inc.
  • TFBS Bioscience Inc.
  • Touchlight Group
  • Univercells Group
  • WuXi AppTec Co., Ltd.
Product Code: MRR-3A2E844FDCF6

The Advanced Therapy Medicinal Products CDMO Market is projected to grow by USD 28.46 billion at a CAGR of 17.92% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.97 billion
Estimated Year [2026] USD 10.43 billion
Forecast Year [2032] USD 28.46 billion
CAGR (%) 17.92%

Advanced Therapy Medicinal Products CDMO Executive Summary

Advanced Therapy Medicinal Products (ATMP) CDMO services are becoming central to the translation of cell therapies, gene therapies, tissue-engineered products, and combined advanced therapies from clinical development to regulated commercial supply. Demand is being shaped by the scientific complexity of autologous and allogeneic platforms, viral and non-viral vector production, plasmid DNA supply, aseptic fill-finish, potency testing, comparability, chain-of-identity controls, and long-term patient follow-up requirements. Unlike conventional biologics manufacturing, ATMP production often requires highly specialized cleanroom infrastructure, closed processing systems, cryogenic logistics, validated analytical methods, and quality systems aligned with Good Manufacturing Practice requirements across multiple jurisdictions. Regulatory agencies such as the U.S. Food and Drug Administration, the European Medicines Agency, and Japan's Pharmaceuticals and Medical Devices Agency have established dedicated pathways and guidance for advanced therapies, reinforcing the need for CDMO partners with deep technical, regulatory, and quality expertise. The sector's strategic importance is also reinforced by the growing number of authorized cell and gene therapies, the expansion of clinical trial activity in oncology, rare diseases, immunology, and regenerative medicine, and the need to improve scalability, reproducibility, and cost efficiency without compromising safety or product identity.

Transformative Shifts in the ATMP CDMO Landscape

The ATMP CDMO landscape is undergoing transformative shifts as developers move from bespoke, manual, and research-grade processes toward industrialized, digitally controlled, and regulatory-ready manufacturing models. A major transition is the adoption of closed and automated manufacturing platforms that reduce contamination risk, improve process consistency, and support decentralized or point-of-care production models where clinically appropriate. Viral vector manufacturing remains a critical bottleneck because lentiviral, adeno-associated viral, and retroviral vectors require complex upstream and downstream workflows, stringent characterization, and scalable transfection or producer-cell technologies. At the same time, non-viral delivery systems, including lipid nanoparticles and transposon-based approaches, are gaining attention as developers seek alternatives that may improve scalability and reduce process constraints. Quality control is also shifting from end-product testing toward integrated process analytics, rapid microbiological methods, digital batch records, and real-time release-enabling strategies. Regulatory expectations are intensifying around comparability after process changes, analytical validation, potency assay relevance, raw material traceability, and donor-cell variability. These shifts are encouraging therapy developers to select CDMO partners earlier in development, particularly those capable of process development, GMP manufacturing, regulatory documentation, analytical lifecycle management, and global clinical supply coordination.

Cumulative Impact of Artificial Intelligence on ATMP CDMO Operations

Artificial intelligence is beginning to influence ATMP CDMO operations by improving process understanding, accelerating analytical interpretation, and strengthening quality decision-making. In cell therapy manufacturing, AI and machine learning can support pattern recognition across donor variability, culture conditions, cell expansion profiles, metabolite trends, and release-test outcomes. In gene therapy and vector production, AI-enabled models can assist with upstream parameter optimization, downstream yield improvement, impurity prediction, and batch deviation investigation. AI is also increasingly relevant in digital quality management through automated document review, anomaly detection in environmental monitoring, predictive maintenance of critical equipment, and faster assessment of batch records. For ATMPs, where every batch can be clinically meaningful and product comparability is complex, AI offers value by connecting manufacturing, analytical, clinical, and supply chain data into more coherent control strategies. However, adoption must be governed by validated systems, data integrity controls, explainability, cybersecurity safeguards, and regulatory alignment. The cumulative impact of AI is therefore not simply faster production; it is the potential to create more robust, transparent, and adaptive manufacturing ecosystems that improve reproducibility, reduce failure risk, and support evidence-based regulatory submissions.

Key Regional Insights Across the ATMP CDMO Ecosystem

Asia-Pacific is strengthening its position in ATMP CDMO activity through supportive regulatory modernization, expanding biomedical infrastructure, and growing clinical development in China, Japan, South Korea, India, Singapore, and Australia. Japan's regenerative medicine framework, South Korea's advanced biopharmaceutical manufacturing capabilities, China's large clinical research base, and Singapore's biomedical manufacturing ecosystem collectively support regional momentum. North America remains a highly mature ATMP CDMO region due to the concentration of clinical trials, authorized advanced therapies, academic medical centers, GMP infrastructure, and regulatory guidance from the FDA for human gene therapy, cellular therapy, and regenerative medicine products. Latin America is progressing more gradually, with Brazil and Mexico serving as important clinical research and biomanufacturing gateways, while regional challenges include uneven infrastructure, reimbursement constraints, and the need for harmonized regulatory capacity. Europe benefits from the EMA's centralized regulatory pathway for ATMPs, established GMP expertise, strong hospital-academic networks, and cross-border clinical research, with Germany, France, Italy, Spain, and the United Kingdom contributing to advanced therapy development and manufacturing capabilities. The Middle East is building interest through healthcare diversification strategies, clinical infrastructure investment, genomics programs, and medical innovation initiatives, particularly in Gulf economies seeking advanced biotechnology capabilities. Africa remains at an earlier stage, with opportunities tied to clinical research capacity building, biomanufacturing partnerships, workforce development, regulatory strengthening, and broader access to advanced biologics infrastructure.

Key Group Insights Shaping ATMP CDMO Strategies

ASEAN is emerging as an important growth corridor for ATMP-enabling services through Singapore's established biomedical manufacturing base, Thailand's medical research initiatives, Malaysia's biopharma development, and regional interest in cell therapy access, though capabilities vary significantly by country. The GCC is increasingly relevant as member states invest in healthcare transformation, genomics, specialty care, and biotechnology infrastructure, creating long-term potential for advanced therapy clinical adoption and localized manufacturing partnerships. The European Union provides one of the most structured regulatory environments for ATMPs through centralized authorization, GMP requirements, pharmacovigilance obligations, and scientific advice mechanisms, making it a key geography for multinational development strategies. BRICS countries present a diverse opportunity set: China and India offer large patient populations and expanding biomanufacturing capacity, Brazil and South Africa provide regional clinical and public health relevance, and Russia maintains scientific capabilities despite geopolitical and regulatory complexities. G7 countries remain influential because they host advanced regulatory agencies, leading research institutions, clinical trial networks, reimbursement decision-makers, and manufacturing expertise that shape global ATMP standards. NATO countries overlap substantially with major North American and European advanced therapy hubs, where supply chain resilience, critical healthcare infrastructure, biosecurity, and strategic manufacturing autonomy are increasingly important considerations for high-value biologics and advanced therapies.

Key Country Insights for ATMP CDMO Development

The United States is the most mature country-level environment for ATMP CDMO services, supported by FDA regulatory pathways, a deep clinical trial base, extensive translational research activity, and a broad network of GMP cell and gene therapy manufacturing capabilities. Canada contributes through strong academic hospitals, regenerative medicine networks, and clinical research infrastructure, while Mexico is gaining relevance for healthcare manufacturing and clinical development support in proximity to the U.S. Brazil is the leading Latin American country for advanced therapy development potential, supported by research institutions and biologics capabilities, although broader commercialization depends on regulatory, reimbursement, and infrastructure maturity. The United Kingdom remains a major ATMP hub due to coordinated cell and gene therapy initiatives, clinical manufacturing expertise, and innovation-focused regulatory engagement. Germany has deep GMP manufacturing competence, engineering strength, and advanced bioprocessing capabilities, while France combines hospital-based research, public biomedical investment, and cell therapy development infrastructure. Russia has scientific and clinical expertise in biotechnology, but international collaboration and supply chain integration are shaped by geopolitical and regulatory constraints. Italy and Spain are important European contributors through academic hospitals, clinical trial activity, and experience with cell therapy programs. China is rapidly expanding its ATMP ecosystem through high clinical research activity, domestic biomanufacturing investment, and regulatory evolution for cell and gene therapies. India is building capabilities through vaccine and biologics manufacturing heritage, clinical research capacity, and emerging cell and gene therapy initiatives. Japan is distinguished by its regenerative medicine regulatory framework and early conditional approval mechanisms for certain regenerative products. Australia supports ATMP development through strong clinical trial operations, hospital networks, and biomedical research, while South Korea is recognized for advanced biomanufacturing, cell therapy innovation, and government support for biopharmaceutical competitiveness.

Actionable Recommendations for ATMP CDMO Industry Leaders

Industry leaders should prioritize integrated ATMP CDMO strategies that connect process development, analytical validation, GMP manufacturing, regulatory planning, and clinical supply logistics from the earliest development stages. Developers should select partners with proven expertise in the specific modality, whether autologous cell therapy, allogeneic cell therapy, viral vector gene therapy, gene-edited cell therapy, tissue-engineered products, or combined ATMPs. Investment in closed processing, automation, digital batch records, electronic chain-of-identity and chain-of-custody systems, and cryogenic logistics can reduce operational risk and improve scalability. Quality strategies should emphasize potency assay development, raw material qualification, comparability protocols, contamination control, and data integrity. Organizations should also diversify critical inputs such as plasmids, viral vectors, cell culture media, single-use systems, and specialized reagents to strengthen supply continuity. Regulatory engagement should be proactive, with early scientific advice and alignment on manufacturing changes, release testing, long-term follow-up, and post-authorization commitments. Finally, leaders should build workforce capabilities in GMP aseptic operations, cell processing, vector analytics, quality assurance, regulatory affairs, and digital manufacturing, as talent constraints remain one of the most persistent barriers in the ATMP CDMO sector.

Research Methodology for ATMP CDMO Insights

This executive summary is developed using a verified secondary research approach grounded in publicly available regulatory, scientific, clinical, and industry sources. Inputs include guidance and public information from major regulatory authorities, peer-reviewed literature on cell and gene therapy manufacturing, clinical trial registry data, public health agency materials, academic publications, manufacturing standards, and documented industry practices in GMP advanced therapy production. The analysis applies qualitative triangulation across regulatory developments, clinical pipeline activity, manufacturing technology trends, supply chain considerations, and regional policy initiatives. The methodology intentionally excludes market sizing, market share estimation, revenue forecasting, or speculative projections. Instead, it focuses on evidence-backed indicators such as regulatory frameworks, authorized therapy categories, manufacturing requirements, infrastructure development, clinical research intensity, quality system needs, and technology adoption patterns. Regional, group, and country insights are synthesized into narrative assessments to support strategic understanding of ATMP CDMO dynamics while maintaining compliance with data integrity, traceability, and non-promotional content standards.

Conclusion: Strategic Outlook for ATMP CDMO Advancement

The Advanced Therapy Medicinal Products CDMO sector is becoming a critical enabler of next-generation healthcare as cell therapies, gene therapies, and regenerative medicine products move toward broader clinical and commercial use. The most competitive CDMO strategies will be built around modality-specific expertise, validated GMP infrastructure, strong analytical science, regulatory readiness, digital quality systems, and resilient supply chains. Regional momentum is strongest where clinical trial ecosystems, regulatory clarity, manufacturing investment, and specialized talent converge, while emerging regions are creating new opportunities through biotechnology capacity building and healthcare innovation programs. Artificial intelligence, automation, closed systems, and advanced analytics are expected to improve manufacturing control and quality performance, but their adoption must remain aligned with validation, compliance, and patient safety requirements. For developers, healthcare systems, and manufacturing partners, the central priority is clear: build scalable, compliant, and scientifically rigorous ATMP CDMO capabilities that can convert complex therapeutic innovation into reliable patient access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Advanced Therapy Medicinal Products CDMO Market, by Product Type

  • 7.1. Introduction
  • 7.2. Cell Therapy Products
    • 7.2.1. Non-stem Cell Therapy
    • 7.2.2. Stem Cell Therapy
  • 7.3. Gene Therapy Products
    • 7.3.1. Germline Therapy
    • 7.3.2. Somatic Gene Therapy
  • 7.4. Tissue Engineered Products

8. Advanced Therapy Medicinal Products CDMO Market, by Service Type

  • 8.1. Introduction
  • 8.2. Analytical Testing & Quality Control
  • 8.3. Manufacturing Services
  • 8.4. Process Development Services
  • 8.5. Regulatory & Compliance Support

9. Advanced Therapy Medicinal Products CDMO Market, by Therapeutic Area

  • 9.1. Introduction
  • 9.2. Cardiology
  • 9.3. Dermatology
  • 9.4. Hematology
  • 9.5. Neurology
  • 9.6. Oncology

10. Advanced Therapy Medicinal Products CDMO Market, by End-User

  • 10.1. Introduction
  • 10.2. Academic & Research Institutes
  • 10.3. Biotechnology Companies
  • 10.4. Pharmaceutical Companies

11. Advanced Therapy Medicinal Products CDMO Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Advanced Therapy Medicinal Products CDMO Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Advanced Therapy Medicinal Products CDMO Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. AGC Biologics Inc.
  • 15.2. Agilent Technologies, Inc.
  • 15.3. Ajinomoto Bio-Pharma Services
  • 15.4. Almac Group Ltd.
  • 15.5. Biomay AG
  • 15.6. BioSpring GmbH
  • 15.7. Catalent, Inc.
  • 15.8. Charles River Laboratories International, Inc.
  • 15.9. CordenPharma International GmbH
  • 15.10. Creative Biogene
  • 15.11. Danaher Corporation
  • 15.12. Eurofins Scientific SE
  • 15.13. Evonik Industries AG
  • 15.14. GenScript Biotech Corporation
  • 15.15. Lonza Group Ltd.
  • 15.16. Polypeptide Group AG
  • 15.17. Recipharm AB
  • 15.18. Rentschler Biopharma SE
  • 15.19. Samsung Biologics Co., Ltd.
  • 15.20. Sartorius AG
  • 15.21. Siegfried AG
  • 15.22. Syneos Health, Inc.
  • 15.23. TFBS Bioscience Inc.
  • 15.24. Touchlight Group
  • 15.25. Univercells Group
  • 15.26. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELL THERAPY PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL THERAPY PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELL THERAPY PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NON-STEM CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL STEM CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL STEM CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL STEM CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE THERAPY PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENE THERAPY PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE THERAPY PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GERMLINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GERMLINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GERMLINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SOMATIC GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SOMATIC GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SOMATIC GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TISSUE ENGINEERED PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TISSUE ENGINEERED PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TISSUE ENGINEERED PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANALYTICAL TESTING & QUALITY CONTROL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANALYTICAL TESTING & QUALITY CONTROL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANALYTICAL TESTING & QUALITY CONTROL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PROCESS DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROCESS DEVELOPMENT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PROCESS DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL REGULATORY & COMPLIANCE SUPPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL REGULATORY & COMPLIANCE SUPPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL REGULATORY & COMPLIANCE SUPPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CARDIOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DERMATOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DERMATOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DERMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEMATOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HEMATOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 115. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 118. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 119. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 121. GCC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 136. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 139. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 140. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 142. G7 ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 143. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 146. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 147. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 149. NATO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 158. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 161. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 162. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 164. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 165. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 168. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 169. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 171. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 172. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 175. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 176. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 178. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 186. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 189. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 190. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 192. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 193. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 196. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 197. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 199. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 200. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 203. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 204. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 206. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 207. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 210. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 211. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 213. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 214. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 217. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 218. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 220. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 228. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 231. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 232. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 234. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 235. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 238. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 239. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 241. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 242. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 245. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 246. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 248. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 249. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 252. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 253. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 255. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 256. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 257. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025